Sarcoma
An Introduction to Sarcoma
Sarcomas are a heterogeneous group of mesenchymal malignancies, with more than 50 subtypes identified. Until recently treatment was limited to standard chemotherapy regimens, however, advances in next-generation sequencing technology have led to the development of molecularly targeted therapy and immunotherapy that offer a personalized treatment approach.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
The five selected Plenary late-breaking abstracts at the ASCO 2026 Annual Meeting in Chicago showcased some of the meeting’s most practice-influencing data. Across prostate cancer, sarcoma, lung cancer and pancreatic cancer, these phase 3 studies demonstrated meaningful improvements in survival outcomes, highlighting the growing impact of perioperative intensification, precision oncology and novel targeted therapies in difficult-to-treat disease settings.
See who the oncology community selected as the rising stars of 2026!
With the second half of 2025 underway, we asked our touchONCOLOGY Future Leaders 2025 to share the developments they believe will shape the future of the field. Here, they highlight five exciting areas that promise to transform practice – not only as the year draws to a close, but well into the future.
The first half of 2025 has brought exciting developments in oncology, with groundbreaking research and real-world progress showcased at ASCO, EHA and many more leading conferences around the world. We asked five of our touchONCOLOGY Future Leaders 2025 to share what they believe has been most impactful so far this year – here’s what they told us.
July is Sarcoma Awareness Month, with a 2025 focus on supporting healthcare professionals in recognising early signs. Dr Rodrigo Munhoz shares key insights from ASCO 2025, where data highlighted how immune and targeted therapies, along with synergistic strategies, are reshaping sarcoma treatment and driving progress across diverse histologies.
This year, we are celebrating our inaugural touchONCOLOGY Future Leaders to recognize the outstanding talent that has entered our field in recent years. These individuals are set to innovate and transform oncology and haematology in the years to come.
"While groundbreaking treatments are transformative, patients often remember the kindness and humanity of their oncologist more than the medicine they receive" Introducing our Future Leaders series, in this interview Dr Rodrigo Munhoz (Oncology Center – Hospital SÃrio-Libanês in Sã...
To further understand the potential of durvalumab (DUR) plus tremelimumab (TRE) in the treatment of soft tissue sarcoma (STS) we spoke with Prof. Viktor Grünwald (University Hospital Essen, Germany). At ESMO 2023, Prof. Grünwald presented results from the MEDISARC ...
Sarcomas are a diverse group of rare muscle, bone and connective tissue tumours. Within soft-tissue sarcoma alone, there are over 70 subtypes, which demonstrate substantial heterogeneity in biology, genetics and clinical behaviour.1Â Further complicating their management is the range of treatment ...
We were delighted to talk with Dr Brian Van Tine (Washington University School of Medicine, Saint Louis, MO, US) around the APROMISS study, investigating the efficacy and safety of AL3818 hydrochloride monotherapy in patients with metastatic or advanced synovial sarcoma. ...
Tenosynovial giant cell tumor (TGCT)—previously referred to as giant cell tumor of the tendon sheath or pigmented villonodular synovitis (PVNS)—is a largely benign, rare, proliferative lesion arising from the synovial lining of joints, bursae, and tendon sheaths.1 This ...
Soft tissue sarcomas represent a group of over 80 rare malignant tumors that arise from tissues of mesenchymal origin throughout the body.1Â Advanced soft tissue sarcoma is treated with single-agent or combination systemic chemotherapy, but is associated with a poor prognosis.2,3Â ...
Professor Jonathan Trent MD, PhD is Associate Director for Clinical Research at the Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida, USA. In this interview, he discusses the challenging state of the art of immunotherapy of gastrointestinal ...
Professor Paolo A. Ascierto is Director of the Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics at the National Tumor Institute, Naples, Italy. Â He obtained his medical degree from the University of Naples, the same institution where he subsequently earned ...
Brain Van Tine (Washington University in St Louis) joins us to discuss the results of the phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft tissue sarcomas who are not candidates for chemotherapy (NCT02300545). ...
At the ASCO 2019 annual meeting, Alona Zer discusses the preliminary results from the interim analysis of a phase II study of nivolumab and ipilimumab in previously treated progressive Classic Kaposi Sarcoma (CKS) (NCT03219671). Questions 1. Could you tell us a little ...
Watch a panel of internationally renowned experts discuss the factors influencing the choice of first-line treatment for patients with advanced soft tissue sarcoma and the interpretation of data from clinical trials in this patient population.
Sarcomas consist of a highly diverse group of malignancies of mesenchymal origin, encompassing more than 80 distinct subtypes and diagnosed in approximately 15,000 patients every year in the US.1 Surgery still represents the mainstay of therapy for patients with localized disease. Although ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
